Inhibrx Valor contable por acción
¿Qué es el Valor contable por acción de Inhibrx?
El Valor contable por acción de Inhibrx, Inc. es 0.51
¿Cuál es la definición de Valor contable por acción?
El valor en libros por acción es el activo de una empresa menos el pasivo dividido por el número de acciones en circulación.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Valor contable por acción de compañías en Sector Health Care en NASDAQ en comparadas con Inhibrx
¿Qué hace Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Empresas con valor contable por acción similar a Inhibrx
- Chong Hing Bank tiene Valor contable por acción de 0.51
- Perfectech International tiene Valor contable por acción de 0.51
- Hancock Jaffe Laboratories Inc tiene Valor contable por acción de 0.51
- Roxgold tiene Valor contable por acción de 0.51
- Witbe SA tiene Valor contable por acción de 0.51
- Planet 13 tiene Valor contable por acción de 0.51
- Inhibrx tiene Valor contable por acción de 0.51
- Perseus Mining tiene Valor contable por acción de 0.51
- Fission Uranium tiene Valor contable por acción de 0.51
- Coronado Global Resources tiene Valor contable por acción de 0.51
- Stereotaxis tiene Valor contable por acción de 0.51
- Planet Green Corp tiene Valor contable por acción de 0.51
- Qianhai Health tiene Valor contable por acción de 0.51